132 related articles for article (PubMed ID: 36434856)
1. UCHL1 promotes cancer stemness in triple-negative breast cancer.
Tian C; Liu Y; Liu Y; Hu P; Xie S; Guo Y; Wang H; Zhang Z; Du L; Lei B; Wang Y; Xue L; Zhang D; Su J; Zhang X; Zhang R; Chen J; Zhang X; Chen L; Li M; Jia Q; Song J; Liu J
Pathol Res Pract; 2022 Dec; 240():154235. PubMed ID: 36434856
[TBL] [Abstract][Full Text] [Related]
2. UCHL1 acts as a prognostic factor and promotes cancer stemness in cervical squamous cell carcinoma.
Jia Q; Wang H; Xiao X; Sun Y; Tan X; Chai J; Yang Y; Yin Z; Li M; Wang K; Liu J
Pathol Res Pract; 2023 Jul; 247():154574. PubMed ID: 37257242
[TBL] [Abstract][Full Text] [Related]
3. Fbxw7 suppresses carcinogenesis and stemness in triple-negative breast cancer through CHD4 degradation and Wnt/β-catenin pathway inhibition.
Xiao G; Lu W; Yuan J; Liu Z; Wang P; Fan H
J Transl Med; 2024 Jan; 22(1):99. PubMed ID: 38268032
[TBL] [Abstract][Full Text] [Related]
4. Deubiquitinase Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGFβ-Induced Breast Cancer Metastasis.
Liu S; González-Prieto R; Zhang M; Geurink PP; Kooij R; Iyengar PV; van Dinther M; Bos E; Zhang X; Le Dévédec SE; van de Water B; Koning RI; Zhu HJ; Mesker WE; Vertegaal ACO; Ovaa H; Zhang L; Martens JWM; Ten Dijke P
Clin Cancer Res; 2020 Mar; 26(6):1460-1473. PubMed ID: 31857432
[TBL] [Abstract][Full Text] [Related]
5. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
6. USP22 Contributes to Chemoresistance, Stemness, and EMT Phenotype of Triple-Negative Breast Cancer Cells by egulating the Warburg Effect via c-Myc Deubiquitination.
Li J; Gao R; Zhang J
Clin Breast Cancer; 2023 Feb; 23(2):162-175. PubMed ID: 36528490
[TBL] [Abstract][Full Text] [Related]
7. UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5.
Li J; Liang Y; Zhou S; Chen J; Wu C
Breast Cancer Res; 2024 Mar; 26(1):44. PubMed ID: 38468288
[TBL] [Abstract][Full Text] [Related]
8. RON Receptor Tyrosine Kinase in Tumorigenic Stemness as a Therapeutic Target of Antibody-drug Conjugates for Eradication of Triple-negative Breast Cancer Stem Cells.
Suthe SR; Yao HP; Weng TH; Wang MH
Curr Cancer Drug Targets; 2023; 23(2):103-117. PubMed ID: 36028965
[TBL] [Abstract][Full Text] [Related]
9. MiR-137 Suppresses Triple-Negative Breast Cancer Stemness and Tumorigenesis by Perturbing BCL11A-DNMT1 Interaction.
Chen F; Luo N; Hu Y; Li X; Zhang K
Cell Physiol Biochem; 2018; 47(5):2147-2158. PubMed ID: 29975921
[TBL] [Abstract][Full Text] [Related]
10. STAT3-induced HLA-F-AS1 promotes cell proliferation and stemness characteristics in triple negative breast cancer cells by upregulating TRABD.
Wu D; Jia H; Zhang Z; Li S
Bioorg Chem; 2021 Apr; 109():104722. PubMed ID: 33618253
[TBL] [Abstract][Full Text] [Related]
11. Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression.
Huang TT; Tseng LM; Chen JL; Chu PY; Lee CH; Huang CT; Wang WL; Lau KY; Tseng MF; Chang YY; Chiang TY; Ueng YF; Lee HC; Dai MS; Liu CY
EBioMedicine; 2020 Apr; 54():102717. PubMed ID: 32268268
[TBL] [Abstract][Full Text] [Related]
12. Decreased expression of autophagy protein LC3 and stemness (CD44+/CD24-/low) indicate poor prognosis in triple-negative breast cancer.
Chang SJ; Ou-Yang F; Tu HP; Lin CH; Huang SH; Kostoro J; Hou MF; Chai CY; Kwan AL
Hum Pathol; 2016 Feb; 48():48-55. PubMed ID: 26772398
[TBL] [Abstract][Full Text] [Related]
13. Deubiquitylase YOD1 regulates CDK1 stability and drives triple-negative breast cancer tumorigenesis.
Han Z; Jia Q; Zhang J; Chen M; Wang L; Tong K; He W; Zhang Y; Zhu W; Qin J; Wang T; Liu T; Ma Y; Chen Y; Zha S; Zhang C
J Exp Clin Cancer Res; 2023 Sep; 42(1):228. PubMed ID: 37667382
[TBL] [Abstract][Full Text] [Related]
14. MiR-4319 Suppress the Malignancy of Triple-Negative Breast Cancer by Regulating Self-Renewal and Tumorigenesis of Stem Cells.
Chu J; Li Y; Fan X; Ma J; Li J; Lu G; Zhang Y; Huang Y; Li W; Huang X; Fu Z; Yin Y; Yuan H
Cell Physiol Biochem; 2018; 48(2):593-604. PubMed ID: 30021199
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA CCAT2 promotes oncogenesis in triple-negative breast cancer by regulating stemness of cancer cells.
Xu Z; Liu C; Zhao Q; Lü J; Ding X; Luo A; He J; Wang G; Li Y; Cai Z; Wang Z; Liu J; Liu S; Li W; Yu Z
Pharmacol Res; 2020 Feb; 152():104628. PubMed ID: 31904506
[TBL] [Abstract][Full Text] [Related]
16. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.
Xu X; Zhang L; He X; Zhang P; Sun C; Xu X; Lu Y; Li F
Biochem Biophys Res Commun; 2018 Jul; 502(1):160-165. PubMed ID: 29792857
[TBL] [Abstract][Full Text] [Related]
17. Study on inhibition of Britannin on triple-negative breast carcinoma through degrading ZEB1 proteins.
Lu H; Wu Z; Wang Y; Zhao D; Zhang B; Hong M
Phytomedicine; 2022 Sep; 104():154291. PubMed ID: 35839735
[TBL] [Abstract][Full Text] [Related]
18. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
[TBL] [Abstract][Full Text] [Related]
19. Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells.
Ling Y; Cao Q; Liu Y; Zhao J; Zhao Y; Li K; Chen Z; Du X; Huo X; Kang H; Chen Z
Breast Cancer; 2021 Mar; 28(2):368-378. PubMed ID: 33047272
[TBL] [Abstract][Full Text] [Related]
20. MiR-92b inhibited cells EMT by targeting Gabra3 and predicted prognosis of triple negative breast cancer patients.
Li YY; Zheng XH; Deng AP; Wang Y; Liu J; Zhou Q; Cheng GY; Jiang Q
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10433-10442. PubMed ID: 31841197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
